Related Experiment Video

Updated: Jul 24, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

L M A Aparicio1, I P Fernandez2, J Cassinello3

  • 1Medical Oncology Department, Hospital Universitario A Coruña, Xubias s/n, 15615, La Coruña, Spain. luis.anton.aparicio@sergas.es.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|April 15, 2017
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) can enhance the immune system's response in metastatic renal cell carcinoma (mRCC). This finding supports combining TKIs with immunotherapy for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • The immune system and angiogenesis are closely linked in cancer development, with complex pro- and anti-angiogenic activities influencing tumor growth.
  • Antiangiogenic molecules can impact immune pathways beyond VEGF signaling, highlighting their broader role in immune regulation.
  • Renal cell carcinoma (RCC) exhibits both angiogenesis and immunosuppression, contributing to impaired antitumor immunity.

Purpose of the Study:

  • To investigate the effects of tyrosine kinase inhibitors (TKIs) on the immune system in metastatic renal cell carcinoma (mRCC).
  • To assess the potential of TKIs in modulating immune responses within the context of RCC's angiogenic and immunosuppressive environment.

Main Methods:

  • Review of existing literature on TKIs, angiogenesis, and immune responses in metastatic renal cell carcinoma.
  • Analysis of preclinical and clinical data regarding the impact of TKIs on immune cell function and cytokine production.

Main Results:

  • Selected TKIs demonstrate antitumor activity in metastatic RCC.
  • TKIs were confirmed to enhance cellular cytokine responses in patients with mRCC.
  • The study highlights a bidirectional relationship between angiogenesis and the immune system in cancer.

Conclusions:

  • TKIs positively influence immune responses in mRCC, suggesting a role beyond direct antiangiogenic effects.
  • The findings provide a rationale for combining TKIs with immunotherapy for improved treatment strategies in mRCC.
  • Understanding TKI-mediated immune modulation is crucial for optimizing cancer therapy.
Keywords:
AngiogenesisImmunomodulationImmunotherapyRenal cell carcinomaTyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.